Properties of CD34(+) CML stem/progenitor cells that correlate with different clinical responses to imatinib mesylate

Imatinib mesylate (IM) induces clinical remissions in chronic-phase chronic myeloid leukemia (CML) patients but IM resistance remains a problem. We recently identified several features of CML CD34(+) stem/progenitor cells expected to confer resistance to BCR-ABL-targeted therapeutics. From a study o...

Полное описание

Сохранить в:
Библиографические подробности
Главные авторы: Jiang, Xiaoyan, Forrest, Donna, Nicolini, Franck, Turhan, Ali, Guilhot, Joelle, Yip, Calvin, Holyoake, Tessa, Jorgensen, Heather, Lambie, Karen, Saw, Kyi Min, Pang, Emily, Vukovic, Ranko, Lehn, Paeta, Ringrose, Ashley, Yu, Miao, Brinkman, Ryan R., Smith, Clay, Eaves, Allen, Eaves, Connie
Формат: Artigo
Язык:Inglês
Опубликовано: American Society of Hematology 2010
Предметы:
Myeloid Neoplasia
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC2951856/
https://ncbi.nlm.nih.gov/pubmed/20574046
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2009-05-222471
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы